ArticleMicrobial biotechnology2021
Benchmarking recombinant Pichia pastoris for 3-hydroxypropionic acid production from glycerol.
Article in Microbial biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 41 citations in OpenAlex.
- Engineering nonconventional yeasts to produce carboxylic acids: Advances and Prospects.Synthetic and systems biotechnology · 2027Review
- Metabolic engineering ofApplied and environmental microbiology · 2026Review
- Overflow metabolism in bacterial, yeast, and mammalian cells: different names, same game.Molecular systems biology · 2025Review
- Advances in metabolic engineering and fermentation for 3-hydroxypropionic acid biosynthesis: a comprehensive review.World journal of microbiology & biotechnology · 2025Review
- A Rewired NADPH-Dependent Redox Shuttle for Testing Peroxisomal Compartmentalization of Synthetic Metabolic Pathways inMicroorganisms · 2024Article
- Applications of the Methylotrophic YeastJournal of fungi (Basel, Switzerland) · 2024Review
- Engineering the synthetic β-alanine pathway in Komagataella phaffii for conversion of methanol into 3-hydroxypropionic acid.Microbial cell factories · 2023Article
- High throughputMicrobial cell factories · 2023Article
- Engineering 3-Hydroxypropionic Acid Production from Glucose inJournal of fungi (Basel, Switzerland) · 2023Article
- Production of 3-Hydroxypropionic Acid from Renewable Substrates by Metabolically Engineered Microorganisms: A Review.Molecules (Basel, Switzerland) · 2023Review
- Combining Metabolic Engineering and Multiplexed Screening Methods for 3-Hydroxypropionic Acid Production inFrontiers in bioengineering and biotechnology · 2022Article
- Benchmarking recombinant Pichia pastoris for 3-hydroxypropionic acid production from glycerol.Microbial biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
The use of the methylotrophic yeast Pichia pastoris (Komagataella phaffi) to produce heterologous proteins has been largely reported. However, investigations addressing the potential of this yeast to produce bulk chemicals are still scarce. In this study, we have studied the use of P. pastoris as a cell factory to produce the commodity chemical 3-hydroxypropionic acid (3-HP) from glycerol. 3-HP is a chemical platform which can be converted into acrylic acid and to other alternatives to petroleum-based products. To this end, the mcr gene from Chloroflexus aurantiacus was introduced into P. pastoris. This single modification allowed the production of 3-HP from glycerol through the malonyl-CoA pathway. Further enzyme and metabolic engineering modifications aimed at increasing cofactor and metabolic precursors availability allowed a 14-fold increase in the production of 3-HP compared to the initial strain. The best strain (PpHP6) was tested in a fed-batch culture, achieving a final concentration of 3-HP of 24.75 g l
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.